Stay updated on Regeneron Press Releases
Sign up to get notified when there's something new on the Regeneron Press Releases page.

Latest updates to the Regeneron Press Releases page
- Check5 days agoChange DetectedNew March 2026 press releases appear on the page, including Regeneron Science Talent Search 2026 recognition and other updates. Older January 2026 press releases are removed, changing the set of headlines presented.SummaryDifference8%

- Check12 days agoChange DetectedTwo new press releases were added to the Press Releases page: 'Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders' (Feb 26, 2026) and 'Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment' (Feb 27, 2026).SummaryDifference2%

- Check20 days agoChange DetectedTwo new press releases were added to the Press Releases page: 'Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)' (February 19, 2026) and 'Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)' (February 24, 2026).SummaryDifference2%

- Check27 days agoChange DetectedAdded a new press release entry titled 'Regeneron Announces Investor Conference Presentations' with timestamp February 11, 2026 4:05 PM EST.SummaryDifference1%

- Check34 days agoChange DetectedA new press release item titled 'Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy' with the date February 10, 2026 7:00 AM EST was added to the Press Releases page.SummaryDifference1%

- Check41 days agoChange DetectedNew press releases were added to the press releases list: Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results (January 30, 2026, 6:30 AM EST) and EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases (February 2, 2026, 7:00 AM EST).SummaryDifference3%

Stay in the know with updates to Regeneron Press Releases
Enter your email address, and we'll notify you when there's something new on the Regeneron Press Releases page.